Jan Holmgren
#72,968
Most Influential Person Now
Swedish physician, microbiologist, and immunologist
Jan Holmgren's AcademicInfluence.com Rankings
Jan Holmgrenphilosophy Degrees
Philosophy
#3460
World Rank
#5593
Historical Rank
Logic
#1171
World Rank
#1854
Historical Rank
Jan Holmgrenbiology Degrees
Biology
#4118
World Rank
#6186
Historical Rank
Microbiology
#141
World Rank
#167
Historical Rank
Immunology
#173
World Rank
#181
Historical Rank
Download Badge
Philosophy Biology
Why Is Jan Holmgren Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jan Roland Holmgren is a Swedish physician, microbiologist, immunologist, and vaccinologist, known for his research on cholera and mucosal immunology, specifically, for his leadership in developing "the world's first effective oral cholera vaccine".
Jan Holmgren's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mucosal immunity and vaccines (2005) (842)
- Evidence for several waves of global transmission in the seventh cholera pandemic (2011) (613)
- Actions of cholera toxin and the prevention and treatment of cholera (1981) (511)
- Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up (1990) (463)
- Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. (1986) (443)
- Tissue Receptor for Cholera Exotoxin: Postulated Structure from Studies with GM1 Ganglioside and Related Glycolipids (1973) (421)
- Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. (1993) (346)
- Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. (1994) (336)
- Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. (1975) (324)
- Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis (2005) (319)
- Protection against cholera in breast-fed children by antibodies in breast milk. (1983) (319)
- FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH (1986) (305)
- The adjuvant effect of Vibrio cholerae and Escherichia coli heat‐labile enterotoxins is linked to their ADP‐ribosyltransferase activity (1992) (305)
- Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. (1977) (282)
- Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. (2003) (275)
- Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina (1997) (270)
- Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. (1985) (263)
- Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues (1989) (256)
- Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. (1997) (243)
- A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. (1997) (242)
- Mucosal immunity and tolerance: relevance to vaccine development (1999) (241)
- Comparison of the Tissue Receptors for Vibrio cholerae and Escherichia coli Enterotoxins by Means of Gangliosides and Natural Cholera Toxoid (1973) (241)
- Cholera Due to Altered El Tor Strains of Vibrio cholerae O1 in Bangladesh (2006) (237)
- Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. (1984) (235)
- Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. (2005) (224)
- Cholera toxin structure, gene regulation and pathophysiological and immunological aspects (2008) (219)
- Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. (1991) (219)
- Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial (2009) (218)
- 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. (2013) (206)
- Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. (1996) (204)
- Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. (1991) (202)
- Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. (1985) (193)
- Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori‐infected mice (2003) (193)
- Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis (2010) (192)
- Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. (2007) (190)
- Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. (1983) (188)
- Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease (1986) (184)
- Mucosal immunity: implications for vaccine development. (1992) (182)
- Nasal and Vaginal Vaccinations Have Differential Effects on Antibody Responses in Vaginal and Cervical Secretions in Humans (2001) (173)
- A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection (2003) (172)
- Cholera Toxin B Subunit as a Carrier Molecule Promotes Antigen Presentation and Increases CD40 and CD86 Expression on Antigen-Presenting Cells (2001) (172)
- Cholera toxin — A foe & a friend (2011) (167)
- Antibodies and Antibody-Secreting Cells in the Female Genital Tract after Vaginal or Intranasal Immunization with Cholera Toxin B Subunit or Conjugates (1998) (164)
- Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. (2005) (163)
- Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. (1989) (162)
- Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid (1976) (156)
- Conformation of protein secreted across bacterial outer membranes: a study of enterotoxin translocation from Vibrio cholerae. (1987) (156)
- Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin (1987) (156)
- Enzyme-Linked Immunosorbent Assays for Cholera Serology (1973) (151)
- Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay (1986) (150)
- B Lymphocytes Promote Expansion of Regulatory T Cells in Oral Tolerance: Powerful Induction by Antigen Coupled to Cholera Toxin B Subunit1 (2008) (149)
- Cholera (2017) (147)
- Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans (1991) (146)
- Induction of compartmentalized B-cell responses in human tonsils (1995) (146)
- Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. (1984) (144)
- Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin (1982) (144)
- Subunit structure of cholera toxin. (1973) (141)
- Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. (1984) (141)
- Recent advances in mucosal vaccines and adjuvants. (2002) (139)
- Efficacy of a Low-Cost, Inactivated Whole-Cell Oral Cholera Vaccine: Results from 3 Years of Follow-Up of a Randomized, Controlled Trial (2011) (138)
- Biodegradable microparticles for oral immunization. (1993) (136)
- Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. (1988) (135)
- Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. (2001) (133)
- Mucosally induced Immunological Tolerance, Regulatory T Cells and the Adjuvant Effect by Cholera Toxin B Subunit (2009) (131)
- Oral Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Generates Both Foxp3+CD25+ and Foxp3−CD25− CD4+ Regulatory T Cells1 (2006) (130)
- Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. (2012) (129)
- Vaccines against mucosal infections. (2012) (128)
- Differential Kinetics and Distribution of Antibodies in Serum and Nasal and Vaginal Secretions after Nasal and Oral Vaccination of Humans (1998) (126)
- Mechanisms of disease and immunity in cholera: a review. (1977) (126)
- Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody (1985) (125)
- Oral tolerization with peptide 336–351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease (2004) (124)
- Cholera Toxin and Its B Subunit Promote Dendritic Cell Vaccination with Different Influences on Th1 and Th2 Development (2003) (124)
- Receptor-like glycocompounds in human milk that inhibit classical and El Tor Vibrio cholerae cell adherence (hemagglutination) (1983) (116)
- Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. (1996) (116)
- Polystyrene-adsorbed gangliosides for investigation of the structure of the tetanus-toxin receptor. (1980) (114)
- Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. (1992) (111)
- Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. (2014) (110)
- Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. (1994) (110)
- A Randomized, Placebo-Controlled Trial of the Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults and Children in a Cholera Endemic Area in Kolkata, India (2008) (109)
- In Vivo Adjuvant-Induced Mobilization and Maturation of Gut Dendritic Cells after Oral Administration of Cholera Toxin1 (2004) (109)
- Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. (1985) (109)
- Antibody Responses in the Lower Respiratory Tract and Male Urogenital Tract in Humans after Nasal and Oral Vaccination with Cholera Toxin B Subunit (1999) (108)
- Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. (1989) (107)
- Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. (1985) (106)
- Sendai virus receptor: proposed recognition structure based on binding to plastic-adsorbed gangliosides. (1980) (106)
- Synthesis of a precursor to the B subunit of heat-labile enterotoxin in Escherichia coli (1981) (105)
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers (2006) (104)
- Development of improved cholera vaccine based on subunit toxoid (1977) (104)
- Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. (1996) (103)
- Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. (1999) (102)
- Interleukin-12 (IL-12) and IL-18 Are Important in Innate Defense against Genital Herpes Simplex Virus Type 2 Infection in Mice but Are Not Required for the Development of Acquired Gamma Interferon-Mediated Protective Immunity (2001) (102)
- Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea. (1989) (101)
- Enterotoxin-producing bacteria and parasites in stools of Ethiopian children with diarrhoeal disease. (1976) (101)
- INTERACTION OF CHOLERA TOXIN AND TOXIN DERIVATIVES WITH LYMPHOCYTES (1974) (100)
- Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. (1998) (98)
- Human circulating specific antibody‐forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers (1995) (97)
- Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection1 (2009) (97)
- Cholera Toxin Enhances Alloantigen Presentation by Cultured Intestinal Epithelial Cells (1993) (97)
- Large-Scale Production of Vibrio cholerae Toxin B Subunit for Use in Oral Vaccines (1993) (96)
- Fixation and inactivation of cholera toxin by GM1 ganglioside. (1973) (96)
- Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. (2007) (95)
- Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. (1994) (94)
- Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women (1980) (93)
- Monoclonal antibodies to cholera toxin with special reference to cross-reactions with Escherichia coli heat-labile enterotoxin (1983) (92)
- Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. (2002) (91)
- Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. (1983) (91)
- Protection against Cholera Toxin after Oral Immunization is Thymus‐Dependent and Associated with Intestinal Production of Neutralizing IgA Antitoxin (1987) (90)
- Transient entry of enterotoxin subunits into the periplasm occurs during their secretion from Vibrio cholerae (1987) (90)
- Intestinal Mucosal Memory and Presence of Memory Cells in Lamina Propria and Peyer's Patches in Mice 2 Years after Oral Immunization with Cholera Toxin (1986) (89)
- Antigen‐Specific In Vitro Suppression of Murine Helicobacter pylori‐Reactive Immunopathological T Cells by CD4+CD25+ Regulatory T Cells (2004) (89)
- Transcutaneous Immunization with Cholera Toxin B Subunit Adjuvant Suppresses IgE Antibody Responses Via Selective Induction of Th1 Immune Responses 1 (2003) (89)
- Identification of a mannose-binding pilus on Vibrio cholerae El Tor. (1991) (87)
- Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor (1996) (87)
- Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. (2006) (81)
- Specific-Antibody-Secreting Cells in the Rectums and Genital Tracts of Nonhuman Primates following Vaccination (1998) (81)
- CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and disease. (2005) (81)
- Reversal of cyclic AMP-mediated intestinal secretion in mice by chlorpromazine. (1978) (80)
- Local Intravaginal Vaccination of the Female Genital Tract (1996) (80)
- Identification ofEscherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure (2007) (79)
- INTESTINAL ANTIBODY RESPONSES AFTER IMMUNISATION WITH CHOLERA B SUBUNIT (1982) (79)
- Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. (2009) (79)
- Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine. (1986) (78)
- Prevention of mucosally induced uveitis with a HSP60‐derived peptide linked to cholera toxin B subunit (2003) (78)
- Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice (1978) (78)
- Boosting of Secretory IgA Antibody Responses in Man by Parenteral Cholera Vaccination (1977) (78)
- Genetic fusion of a non‐toxic heat‐stable enterotoxin‐related decapeptide antigen to cholera toxin B‐subunit (1988) (76)
- Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. (1986) (76)
- Cholera and the immune response. (1983) (76)
- Impaired mucosal antibody response to cholera toxin in vitamin A-deficient rats immunized with oral cholera vaccine (1993) (76)
- IMPACT OF B SUBUNIT KILLED WHOLE-CELL AND KILLED WHOLE-CELL-ONLY ORAL VACCINES AGAINST CHOLERA UPON TREATED DIARRHOEAL ILLNESS AND MORTALITY IN AN AREA ENDEMIC FOR CHOLERA (1988) (76)
- Local and systemic antibody responses to naturally acquired enterotoxigenic Escherichia coli diarrhea in an endemic area. (1986) (75)
- Broad Up-Regulation of Innate Defense Factors during Acute Cholera (2007) (75)
- Topical immunization strategies (2010) (75)
- Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. (1993) (75)
- Nonimmunoglobulin fraction of human milk inhibits bacterial adhesion (hemagglutination) and enterotoxin binding of Escherichia coli and Vibrio cholerae (1981) (74)
- PROTECTIVE ANTITOXIC CHOLERA IMMUNITY IN MICE: INFLUENCE OF ROUTE AND NUMBER OF IMMUNIZATIONS AND MODE OF ACTION OF PROTECTIVE ANTIBODIES (1978) (74)
- Biotype as determinant of natural immunising effect of cholera (1991) (73)
- Sublingual Immunization Protects against Helicobacter pylori Infection and Induces T and B Cell Responses in the Stomach (2010) (73)
- Gangliosides as receptors for bacterial toxins and Sendai virus. (1980) (73)
- Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside. (1981) (72)
- Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. (1989) (72)
- An oral B subunit: whole cell vaccine against cholera. (1992) (72)
- Local and Systemic Immune Responses to Rectal Administration of Recombinant Cholera Toxin B Subunit in Humans (2001) (71)
- A Double Mutant Heat-Labile Toxin from Escherichia coli, LT(R192G/L211A), Is an Effective Mucosal Adjuvant for Vaccination against Helicobacter pylori Infection (2013) (71)
- Dendritic Cell-Mediated Induction of Mucosal Cytotoxic Responses following Intravaginal Immunization with the Nontoxic B Subunit of Cholera Toxin1 (2006) (70)
- CHLORPROMAZINE REDUCES FLUID-LOSS IN CHOLERA (1979) (70)
- Natural Killer Cells and Helicobacter pylori Infection: Bacterial Antigens and Interleukin-12 Act Synergistically To Induce Gamma Interferon Production (2005) (70)
- Cloning and sequencing of Vibrio cholerae mannose‐sensitive haemagglutinin pilin gene: localization of mshA within a cluster of type 4 pilin genes (1994) (70)
- Development of an Oral Vaccine Against Enterotoxigenic Escherichia coli Diarrhea (1991) (69)
- Long‐Term Cholera Antitoxin Memory in the Gut can be Triggered to Antibody Formation Associated with Protection within Hours of an Oral Challenge Immunization (1987) (69)
- Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-beta-secreting cells and suppressing chemokine expression. (2000) (69)
- Gamma‐Interferon‐Mediated Down‐Regulation of Electrolyte Secretion by Intestinal Epithelial Cells: A Local Immune Mechanism? (1989) (68)
- Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. (1999) (68)
- Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. (1996) (67)
- CD11chigh Dendritic Cells Are Essential for Activation of CD4+ T Cells and Generation of Specific Antibodies following Mucosal Immunization1 (2009) (66)
- Role of PCF8775 antigen and its coli surface subcomponents for colonization, disease, and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits (1988) (66)
- New-generation vaccines against cholera (2011) (66)
- Systemic and Mucosal Immune Responses in Mice after Mucosal Immunization with Group B Streptococcus Type III Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccine (2000) (66)
- Protection against Experimental Helicobacter pylori Infection after Immunization with Inactivated H. pylori Whole-Cell Vaccines (2002) (66)
- Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. (2000) (65)
- Mucosal immunity and vaccination. (1991) (63)
- Vaccines against enteric infections for the developing world (2015) (63)
- Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. (1984) (62)
- Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture (1989) (62)
- Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates (1995) (61)
- Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model of Helicobacter pylori Infection (2003) (61)
- Cholera Toxin, and the Related Nontoxic Adjuvants mmCT and dmLT, Promote Human Th17 Responses via Cyclic AMP–Protein Kinase A and Inflammasome-Dependent IL-1 Signaling (2015) (60)
- Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. (1999) (59)
- Cholera antibody production in vitro by peripheral blood lymphocytes following oral immunization of humans and mice. (1985) (57)
- Protective capacity of antibodies against E. coli O antigen with special reference to the avidity. (1974) (56)
- Effects of Oral Vaccination and Immunomodulation by Cholera Toxin on Experimental Helicobacter pylori Infection, Reinfection, and Gastritis (2002) (55)
- Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. (1993) (54)
- Roles of different coli surface antigens of colonization factor antigen II in colonization by and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits (1990) (53)
- New cholera vaccines. (1989) (53)
- Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization (1975) (53)
- Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine (1996) (51)
- A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. (2011) (51)
- Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. (1990) (51)
- Ten years of the Global Alliance for Vaccines and Immunization: challenges and progress (2010) (51)
- Antibody responses to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. (1981) (51)
- Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA (2003) (51)
- Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin (1979) (50)
- CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. (2004) (50)
- Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co‐administration with free toxin as adjuvant (2000) (49)
- Enteric vaccines for the developing world: a challenge for mucosal immunology (2009) (49)
- Antisense inhibition of delta-opioid receptor gene function in vivo by peptide nucleic acids. (2000) (49)
- Sublingual vaccination (2011) (48)
- Interaction of Bordetella pertussis with mast cells, modulation of cytokine secretion by pertussis toxin (2001) (47)
- Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. (1999) (46)
- Sublingual ‘Oral Tolerance’ Induction with Antigen Conjugated to Cholera Toxin B Subunit Generates Regulatory T Cells that Induce Apoptosis and Depletion of Effector T Cells (2007) (46)
- Vaccine Protection of Bangladeshi Infants and Young Children Against Cholera: Implications for Vaccine Deployment and Person-to-Person Transmission (2008) (46)
- Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. (1984) (46)
- Bacterial enteric infections and vaccine development. (1992) (46)
- Establishment of an Adult Mouse Model for Direct Evaluation of the Efficacy of Vaccines against Vibrio cholerae (2009) (45)
- The binding of colonization factor antigens of enterotoxigenic Escherichia coli to intestinal cell membrane proteins. (1990) (45)
- Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. (1991) (44)
- Cross-reactivity between heat labile enterotoxins of Vibrio cholerae and Escherichia coli in neutralization tests in rabbit ileum and skin. (2009) (44)
- Immunodiffusion studies on Escherichia coli. 1. Identification of O, K and H antigens in an O6 strain. (2009) (44)
- Sublingual Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Induces Foxp3+CD25+CD4+ Regulatory T Cells and Suppresses Delayed‐Type Hypersensitivity Reactions (2006) (44)
- Novel Carbohydrate Binding Site Recognizing Blood Group A and B Determinants in a Hybrid of Cholera Toxin and Escherichia coli Heat-labile Enterotoxin B-subunits* (2000) (44)
- Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development. (1993) (44)
- Current status and future prospects for a vaccine against schistosomiasis (2004) (44)
- Oligomeric structure of cholera toxin: characteristics of the H and L subunits. (1975) (43)
- Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate (1997) (43)
- Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili (1992) (43)
- Antitoxic cholera immunity in mice: influence of antigen deposition on antitoxin-containing cells and protective immunity in different parts of the intestine. (1980) (43)
- "PERFEXT": a direct method for quantitative assessment of cytokine production in vivo at the local level. (1997) (43)
- Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers. (1994) (42)
- Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin. (1986) (41)
- Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. (1995) (41)
- Immunological aspects of urinary tract infections. (1975) (41)
- Cholera Toxin B Subunit as Transmucosal Carrier‐Delivery and Immunomodulating System for Induction of Antiinfectious and Antipathological Immunity a (1996) (41)
- Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. (2004) (40)
- Chlorpromazine Reverses Diarrhea in Piglets Caused by Enterotoxigenic Escherichia coli (1979) (40)
- B Lymphocytes Treated In Vitro with Antigen Coupled to Cholera Toxin B Subunit Induce Antigen-Specific Foxp3+ Regulatory T Cells and Protect against Experimental Autoimmune Encephalomyelitis (2012) (40)
- The maltose regulon of Vibrio cholerae affects production and secretion of virulence factors (1994) (40)
- Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. (2013) (40)
- Local Antibody Production in Experimental Pyelonephritis: Amount, Avidity, and Immunoglobulin Class (1974) (39)
- Five-year immunologic memory in Swedish volunteers after oral cholera vaccination. (1988) (39)
- Correlates of protection for enteric vaccines. (2017) (39)
- A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. (2003) (39)
- Analysis of expression of toxin-coregulated pili in classical and El Tor Vibrio cholerae O1 in vitro and in vivo (1992) (39)
- Purification of Vibrio cholerae soluble hemagglutinin and development of enzyme-linked immunosorbent assays for antigen and antibody quantitations (1983) (39)
- Binding specificity of monoclonal antibodies to ganglioside, Fuc-GM1. (1986) (38)
- Tissue receptor for cholera exotoxin: structural requirements of G11 ganglioside in toxin binding and inactivation. (1974) (38)
- Cholera toxin and the adenylate cyclase-activating signal. (1976) (38)
- Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. (2009) (37)
- Amplified ELISPOT assay for the detection of HIV-specific antibody-secreting cells in subhuman primates. (1992) (37)
- Differential expression of intestinal membrane transporters in cholera patients (2007) (37)
- Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. (1994) (36)
- Virus‐specific antibody production and polyclonal B‐cell activation in the intestinal mucosa of HIV‐infected individuals (1995) (36)
- Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin (1989) (36)
- Genetic fusion of human insulin B‐chain to the B‐subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo (2002) (36)
- Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development (1996) (35)
- Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera (1994) (35)
- Monoclonal antibodies raised against NeuAc alpha 2-6neolactotetraosylceramide detect carcinoma-associated gangliosides. (1985) (35)
- Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection. (2001) (34)
- Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells (1988) (34)
- Structural studies of the Vibrio cholerae O-antigen. (1979) (34)
- Cholera toxin, ganglioside receptors and the immune response. (1976) (34)
- Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. (2000) (34)
- Antibodies in human serum and milk induced by enterobacteria and food proteins. (2008) (34)
- Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. (2009) (33)
- Development of Stable Vibrio cholerae O1 Hikojima Type Vaccine Strains Co–Expressing the Inaba and Ogawa Lipopolysaccharide Antigens (2014) (33)
- Recombinant fusion protein for simple detection of Escherichia coli heat-stable enterotoxin by GM1 enzyme-linked immunosorbent assay (1990) (33)
- Structural basis for differential receptor binding of cholera and Escherichia coli heat‐labile toxins: influence of heterologous amino acid substitutions in the cholera B‐subunit (1997) (33)
- Recent developments in mucosal immunomodulatory adjuvants. (2003) (33)
- Immunoactive chimeric ST‐LT enterotoxins of Escherichia coli generated by in vitro gene fusion (1986) (32)
- The Protective Effect against E. coli of O and K Antibodies of Different Immunoglobulin Classes (1972) (32)
- A radial immune-gel filtration method for characterization and quantitation of macromolecules. (1971) (32)
- CD11c Dendritic Cells Are Essential for Activation of CD4 T Cells and Generation of Specific Antibodies following Mucosal Immunization (2009) (32)
- Multiple attacks of hepatitis in drug addicts: biochemical, immunochemical, and morphologic characteristics. (1973) (31)
- Novel Immunostimulatory Agent Based on CpG Oligodeoxynucleotide Linked to the Nontoxic B Subunit of Cholera Toxin1 (2006) (31)
- Characterization of enterotoxin and soluble hemagglutinin from Vibrio mimicus: identity with V. cholerae O1 toxin and hemagglutinin (1985) (31)
- Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I‐restricted cytotoxic T cells and the rejection of a cognate antigen‐expressing model tumor (2004) (31)
- IgA isotype restriction in the mucosal but not in the extramucosal immune response after oral immunizations with cholera toxin or cholera B subunit. (1983) (31)
- Chlorpromazine inhibits cholera toxin-induced intestinal hypersecretion. (1977) (31)
- Experimental Studies on Cholera Immunization II. Evidence for Protective Antitoxic Immunity Mediated by Serum Antibodies as Well as Local Antibodies (1972) (30)
- Intestinal antibody responses to oral vaccination in HIV‐infected individuals (1993) (30)
- Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine. (1989) (30)
- Intranasal Immunization of Mice with Group B Streptococcal Protein Rib and Cholera Toxin B Subunit Confers Protection against Lethal Infection (2004) (30)
- An optimized automated assay for determination of metabolic stability using hepatocytes: assay validation, variance component analysis, and in vivo relevance. (2007) (29)
- Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae. (2016) (29)
- Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens. (2011) (29)
- Cholera toxin B subunit (CTB) entrapped in microparticles shows comparable immunogenicity to CTB mixed with whole cholera toxin following oral immunization (1995) (28)
- Group B Streptococcus Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccines Prepared by Different Methods for Intranasal Immunization (2001) (28)
- Purification of El Tor cholera enterotoxins and comparisons with classical toxin. (1990) (28)
- Detoxification of Cholera Toxin without Removal of Its Immunoadjuvanticity by the Addition of (STa-related) Peptides to the Catalytic Subunit (2002) (27)
- An oral B subunit-whole cell vaccine against cholera: from concept to successful field trial. (1987) (26)
- Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. (2008) (26)
- Immunochemical Studies of Two Cholera Toxin-Containing Standard Culture Filtrate Preparations of Vibrio cholerae (1971) (26)
- Impaired IFN-γ production after stimulation with bacterial components by natural killer cells from gastric cancer patients. (2011) (25)
- Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant. (2018) (25)
- A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens. (2016) (25)
- Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. (2011) (25)
- Protective Vaccination Against Genital Herpes Simplex Virus Type 2 (HSV‐2) Infection in Mice is Associated with a Rapid Induction of Local IFN‐γ‐Dependent RANTES Production Following a Vaginal Viral Challenge (2001) (25)
- Circulating Cholera Antitoxin Memory Cells in the Blood One Year after Oral Cholera Vaccination in Humans (1987) (25)
- Enhanced immunological tolerance against allograft rejection by oral administration of allogeneic antigen linked to cholera toxin B subunit. (2000) (24)
- Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier. (1994) (24)
- Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria. (2010) (24)
- Swedish Agency for Research Cooperation with Developing Countries. Prospects for public health benefits in developing countries from new vaccines against enteric infections. (1991) (24)
- Cholera toxin expression by El Tor Vibrio cholerae in shallow culture growth conditions. (2014) (24)
- Immunity to Vibrio cholerae Infection (1994) (24)
- Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. (2001) (24)
- Oral tolerance induction by mucosal administration of cholera toxin B‐coupled antigen involves T‐cell proliferation in vivo and is not affected by depletion of CD25+ T cells (2006) (24)
- Anatomic Segmentation of the Intestinal Immune Response in Nonhuman Primates: Differential Distribution of B Cells after Oral and Rectal Immunizations to Sites Defined by Their Source of Vascularization (1999) (24)
- Protein reagent modification of cholera toxin: characterization of effects on antigenic, receptor-binding and toxic properties. (1975) (24)
- Synthesis in Vibrio cholerae and secretion of hepatitis B virus antigens fused to Escherichia coli heat-labile enterotoxin subunit B. (1991) (23)
- Use of chlorpromazine in the treatment of cholera and other severe acute watery diarrheal diseases (1982) (23)
- Characterization of precipitating antibodies to E. coli O antigen in infants and children with acute pyelonephritis. (1971) (23)
- Structure and Function of Enterotoxins and Their Receptors (1980) (23)
- Role of local IgA antitoxin-producing cells for intestinal protection against cholera toxin challenge. (1989) (23)
- A recombinant Escherichia coli heat-stable enterotoxin (STa) fusion protein eliciting anti-STa neutralizing antibodies. (1991) (23)
- B‐Cell Activation in Duodenal Mucosa after Oral Cholera Vaccination in IgA Deficient Subjects with or without IgG Subclass Deficiency (1993) (23)
- CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. (2005) (22)
- Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model (2012) (22)
- When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks? (2014) (22)
- Receptors for cholera toxin and Escherichia coli heat-labile enterotoxin revisited. (1994) (22)
- Immunodiffusion studies on Escherichia coli. 2. Characterization of antigens used for passive haemagglutination with an O 6 strain as model. (2009) (22)
- Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. (2004) (22)
- Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition. (1991) (22)
- Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam. (2001) (22)
- Nasal Administration of Schistosoma mansoni Egg Antigen‐Cholera B Subunit Conjugate Suppresses Hepatic Granuloma Formation and Reduces Mortality in S. mansoni‐Infected Mice (2001) (21)
- Induction of specific antibody responses in the human nasopharyngeal mucosa. (1995) (21)
- The primary and secondary antibody response to Escherichia coli O6 lipopolysaccharide analysed at the humoral and cellular level. Amount and avidity of the antibodies in relation to protective capacity. (1973) (21)
- Studies of methods for quantitation of agglutinins and precipitins to Escherichia coli O and K antigens. (1970) (21)
- Protective Oral Cholera Vaccine Based on a Combination of Cholera Toxin B Subunit and Inactivated Cholera Vibrios (1994) (21)
- Human gastric B cell responses can be induced by intestinal immunisation (2001) (21)
- CD8– Natural Killer Cells Are Greatly Enriched in the Human Gastrointestinal Tract and Have the Capacity to Respond to Bacteria (2010) (21)
- Intestinal and circulating antibody‐forming cells in IgA‐deficient individuals after oral cholera vaccination (1994) (21)
- Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer. (1992) (20)
- Non-O1 Vibrio cholerae in Thailand: homology with cloned cholera toxin genes (1985) (20)
- Oral Cholera Vaccines (1986) (20)
- Enteric infections in an endemic area induce a circulating antibody-secreting cell response with homing potentials to both mucosal and systemic tissues. (1998) (20)
- Retrospective Analysis of Serotype Switching of Vibrio cholerae O1 in a Cholera Endemic Region Shows It Is a Non-random Process (2016) (20)
- Cholera as a model for research on mucosal immunity and development of oral vaccines (1992) (20)
- The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. (1993) (20)
- Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli. (1995) (20)
- High frequency of spontaneous interferon‐gamma‐producing cells in human tonsils: role of local accessory cells and soluble factors (1993) (20)
- Tumor‐cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small‐cell lung carcinoma (1991) (19)
- Diminished immunopathology in Schistosoma mansoni infection following intranasal administration of cholera toxin B‐immunodominant peptide conjugate correlates with enhanced transforming growth factor‐β production by CD4 T cells (2002) (19)
- Synthesis on nontoxic, antibody-binding Escherichia coli heat-stable enterotoxin (STa) peptides (1988) (19)
- Development of oral vaccines against cholera and enterotoxinogenic Escherichia coli diarrhea. (1990) (19)
- INHIBITION OF BACTERIAL ADHESION AND TOXIN BINDING BY GLYCOCONJUGATE AND OLIGOSACCHARIDE RECEPTOR ANALOGUES IN HUMAN MILK (1987) (19)
- Fusion of genes encoding Escherichia coli heat-stable enterotoxin and outer membrane protein OmpC (1989) (19)
- Immunoglobulin and specific-antibody synthesis in vitro by enteral and nonenteral lymphoid tissues after subcutaneous cholera immunization (1977) (19)
- Expression of Cholera Toxin under Non-AKI Conditions in Vibrio cholerae El Tor Induced by Increasing the Exposed Surface of Cultures (2004) (19)
- Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice. (2012) (19)
- Important Role for FcγRIIB on B Lymphocytes for Mucosal Antigen-Induced Tolerance and Foxp3+ Regulatory T Cells (2013) (18)
- Immunoglobulin and Specific-Antibody Synthesis In Vitro by Enteral and Nonenteral Lymphoid Tissues After Subcutaneous Cholera Immunization (1977) (18)
- Patterns of immunoglobulins in acute viral hepatitis: relation to hepatitis-associated antigen. (1972) (18)
- An Antigenic Relationship Between Kidney and Certa in Escherichia coli Strains (1971) (18)
- Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit. (1993) (18)
- An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses (2019) (17)
- The validity of the ammonium sulphate precipitation technique of estimation of antibody amount and avidity. (1973) (17)
- New vaccines against bacterial enteric infections. (1990) (17)
- The antibody response in rabbits to E. coli K antigen. (1970) (17)
- Cholera as a model for research on mucosal immunity and development of oral vaccines. (1992) (17)
- Surface expression of Helicobacter pylori HpaA adhesion antigen on Vibrio cholerae, enhanced by co-expressed enterotoxigenic Escherichia coli fimbrial antigens. (2017) (17)
- Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccines (2010) (17)
- Controlled trial of chlorpromazine as antisecretory agent in patients with cholera hydrated intravenously. (1982) (16)
- Strong biotype and serotype cross-protective antibacterial and antitoxic immunity in rabbits after cholera infection. (1986) (16)
- Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation. (2011) (16)
- Comparison oftheTissue Receptors forVibrio cholerae andEscherichia coli Enterotoxins by Means ofGangliosides andNatural Cholera Toxoid (1973) (16)
- Intestinal immune response to cholera toxin: dependence on route and dosage of antigen for priming and boosting (1980) (15)
- Cholera Toxin Induces a Transient Depletion of CD8+ Intraepithelial Lymphocytes in the Rat Small Intestine as Detected by Microarray and Immunohistochemistry (2005) (15)
- Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid (1998) (15)
- Vibriocidal Antibody Responses to a Bivalent Killed Whole-Cell Oral Cholera Vaccine in a Phase III Trial in Kolkata, India (2014) (15)
- Structure and arrangement of the cholera toxin genes in Vibrio cholerae O139. (1994) (15)
- An Update on Cholera Immunity and Current and Future Cholera Vaccines (2021) (15)
- Urgent need of cholera vaccines in public health-control programs. (2009) (14)
- A randomized, controlled trial of the toxin-blocking effects of B subunit in family members of patients with cholera. (1984) (14)
- Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines (2019) (14)
- MATERNAL CHOLERA IMMUNISATION AND SECRETORY IgA IN BREAST MILK (1980) (14)
- Cholera toxin enhances antigen presentation. (1995) (14)
- Cholera and related diarrheas : molecular aspects of a global health problem : [proceedings of the] 43rd Nobel Symposium, Stockholm, August 6-11, 1978 (1980) (14)
- 3.8. Oral Vaccination, Mucosal Immunity and Oral Tolerance with Special Reference to Cholera Toxin (1996) (14)
- Enterotoxigenic Escherichia coli diarrhea in an endemic area prepares the intestine for an anamnestic immunoglobulin A antitoxin response to oral cholera B subunit vaccination (1988) (13)
- Genital Antibody Responses in Mice after Intranasal Infection with an Attenuated Candidate Vector Strain ofBordetella pertussis (2000) (13)
- Exploration of mucosal immunity in humans: relevance to vaccine development. (1994) (13)
- Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin (2017) (13)
- The use of chlorpromazine in the treatment of cholera and other severe acute watery diarrheal diseases. (1982) (13)
- IgG and IgA subclass distribution of antitoxin antibody responses after oral cholera vaccination or cholera disease. (1988) (13)
- Effect of protein release rates from tablet formulations on the immune response after sublingual immunization. (2012) (13)
- Immunohistochemical detection of two small cell lung carcinoma‐associated antigens defined by MAbs F12 and 123C3 in bronchoscopy biopsy tissues (1991) (13)
- Colorectal carcinomas have a characteristic ganglioside pattern. (1983) (13)
- Expression of the Escherichia coli lamB gene in Vibrio cholerae. (1986) (13)
- Interaction of cholera toxin and membrane GM 1 ganglioside of small intestine ( mucosal receptors (12)
- PRECIPITATING ANTIBODIES TO E. COLI O ANTIGENS: A SUGGESTED DIFFERENCE IN THE ANTIBODY RESPONSE OF INFANTS AND CHILDREN WITH FIRST AND RECURRENT ATTACKS OF PYELONEPHRITIS (1969) (12)
- Enterotoxin-Specific Immunoglobulin E Responses in Humans after Infection or Vaccination with Diarrhea-Causing Enteropathogens (2000) (12)
- Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies. (2008) (12)
- Alteration of the antibody response to Escherichia coli O antigen in mice by prior exposure to various somatic antigens. (1975) (12)
- Differential effect of cholera toxin on CD45RA+ and CD45RO+ T cells: specific inhibition of cytokine production but not proliferation of human naive T cells (2000) (12)
- A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling (2020) (12)
- Mucosal immune response to cholera toxin--cellular basis of memory and adjuvant action. (1988) (12)
- Development of vaccines and drugs against diarrhea : 11th Nobel Conference, Stockholm, 1985 (1986) (12)
- Vaccination with Bordetella pertussis-Pulsed Autologous or Heterologous Dendritic Cells Induces a Mucosal Antibody Response In Vivo and Protects against Infection (2001) (12)
- Depth profiling of cells and tissues by using C60+ and SF5+ as sputter ions (2008) (11)
- Quantitation of vibriocidal antibodies using agar plague techniques. (1971) (11)
- A paper disc technique for studying antibacterial synergism. (2009) (11)
- Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine. (2020) (11)
- Adjuvants Enhance the Induction of Germinal Center and Antibody Secreting Cells in Spleen and Their Persistence in Bone Marrow of Neonatal Mice (2019) (11)
- CA-50 as a tumour marker for monitoring colorectal cancer: antigen rises in patients postoperatively precede clinical manifestations of recurrence. (1988) (11)
- Interferon production by Shigella flexneri-infected fibroblasts depends upon intracellular bacterial metabolism (1990) (11)
- CA 50 Determination in body fluids: Can we screen patients at risk for gastric cancer? (1991) (11)
- Significance of amount and avidity of E. coli O antibodies for manifestation of their serological and protective properties. A preliminary study. (1972) (11)
- Induction and Expression of Intestinal Humoral Immunity in HIV-Infected Individuals: Prospects for Vaccination against Secondary Enteric Infections (1998) (10)
- Chimeric Vaccines Against Japanese Encephalitis, Dengue, and West Nile (2004) (10)
- Monoclonal Antibodies and Immunodetection Methods for Vibrio cholerae and Escherichia coli Enterotoxins (1986) (10)
- The bactericidal effect of normal human serum on e. coli strains from normals and from patients with urinary tract infections (2005) (10)
- Changes in intestinal fluid and mucosal immune responses to cholera toxin in Giardia muris infection and binding of cholera toxin to Giardia muris trophozoites (1985) (10)
- Fucosyl-GM1 — A ganglioside associated with small cell lung carcinomas (1984) (10)
- Quantitation of Escherichia coli O antibodies by direct and indirect agglutination in comparison with a radioimmunoassay. (1975) (10)
- Sensitization and development of tolerance via the gut (1993) (10)
- Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies. (2009) (9)
- CpG oligodeoxynucleotides and mobilization of innate mucosal immunity: tasks and tactics. (2006) (9)
- Chapter 42 – Mucosal Immunity to Bacteria (2005) (9)
- Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFκB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT (2019) (9)
- A case for control of cholera in Africa by vaccination. (2012) (9)
- Immunoassays based on plastic-adsorbed gangliosides. (1980) (9)
- In vivo modulation of intracellular cAMP and cell growth of a lymphatic tumour in mice by cholera toxin. (1977) (8)
- Immunity to enterotoxin-producing bacteria (1992) (8)
- Oral immunization against cholera. (1989) (8)
- Current status of an oral B subunit whole cell cholera vaccine. (1983) (8)
- Chemical modification of cholera toxin for characterization of antigenic receptor‐binding and toxic sites (1974) (8)
- Antigenic relationships between kidney and enteric bacteria (1975) (8)
- An antigenic relationship between kidney and certain Escherichia coli strains. (1971) (8)
- Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes (1995) (8)
- Oral tolerance and anti-pathological vaccines. (1999) (8)
- Mechanism of action of cholera toxin. Specific inhibition of toxin‐induced activation of adenylate cyclase (1975) (8)
- Thermolysin treatment; an improved dispersion technique for isolating functional lymphoid cells from intestinal tissues (1990) (8)
- Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin-β1 as strongly upregulated molecules involved in adjuvant activity (2019) (7)
- 5 year effi cacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata , India : a cluster-randomised , double-blind , placebo-controlled trial (2013) (7)
- Gangliosides as Receptors for Cholera Toxin, Tetanus Toxin, and Sendai Virus (1980) (7)
- Experimental studies on cholera immunization. 1. The response of neutralizing and vibriocidal antibodies in rabbits after immunization with culture filtrate material from V. cholerae. (2009) (7)
- Interaction of cholera toxin and toxin derivatives with lymphocytes. II. Modulating effects of cholera toxin on in vivo humoral and cellular immune responses. (1976) (7)
- Helicobacter pylori Infection of the Gastric Mucosa (2015) (7)
- Experimental studies on cholera immunisation: the protective immunogenicity in rabbits of monomeric and polymeric crude exotoxin. (1973) (7)
- Changes in intestinal fluid transport and immune responses to enterotoxins due to concomitant parasitic infection. (1980) (7)
- Lymphoid cell populations dynamics and the mucosal immune response in humans (1990) (6)
- Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation. (2017) (6)
- Preparation and preclinical evaluation of a freeze-dried formulation of a novel combined multivalent whole-cell/B-subunit oral vaccine against enterotoxigenic Escherichia coli diarrhea. (2016) (6)
- Extracellular secretion of STa heat‐stable enterotoxin by Escherichia coli after fusion to a heterologous leader peptide (1993) (6)
- In vivo suppression of allograft rejection by cyclic AMP increasing agents. (1979) (6)
- Tumor marker antigens : properties and usefulness of cardinoma associated antigens CEA, CA 19-9 and CA-50 (1985) (6)
- A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh. (2021) (6)
- Detection of caeruloplasmin in bovine milk and blood serum (1967) (6)
- Intestinal immune responsiveness in HIV-infected individuals. (1995) (6)
- Enterotoxin antibodies in relation to diarrhoea in Swedish soldiers in Cyprus. (1977) (6)
- A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer (1988) (6)
- Weak serum and intestinal antibody responses to Vibrio cholerae soluble hemagglutinin in cholera patients (1984) (6)
- Immunopathogenesis and prevention of uveitis with the Behçet's disease-specific peptide linked to cholera toxin B. (2003) (6)
- Enhancement of the IgG antibody production to Escherichia coli O antigen by prior exposure to serologically different E. coli bacteria. (1974) (5)
- Vaccine development for the control of cholera and related toxin-induced diarrhoeal diseases. (1985) (5)
- The Women Writers in Schiller's Horen: Patrons, Petticoats, and the Promotion of Weimar Classicism (2010) (5)
- An antigenic relationship between human kidney, colon and the common antigen of enterobacteriaceae. (1972) (5)
- Adoptive transfer of mucosal T cells or dendritic cells from animals fed with cholera toxin B subunit alloantigen conjugate induces allogeneic T cell tolerance. (2001) (5)
- Asymptomatic bacteriuria--a serious disease? (1972) (5)
- Modern History of Cholera Vaccines and the Pivotal Role of icddr,b (2021) (5)
- Vaccines Against Diarrheal Diseases (1999) (5)
- Mucosal adjuvants based on cholera toxin and E . coli heat-labile enterotoxin (2006) (5)
- Impaired mucosal immune response in vitamin A deficient rats immunized with oral cholera vaccine. (1995) (5)
- Gangliosides of human intestinal mucosa: detection of a possible fetal antigen. (1982) (5)
- Evaluation ofa Ganglioside Immunosorbent Assayfor Detection ofEscherichia coli Heat-Labile Enterotoxin (1979) (5)
- Immunological cross-reactivity between human kidney and certain E. coli and streptococcal strains. (1972) (5)
- Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin. (2008) (5)
- B cells treated with CTB-p210 acquire a regulatory phenotype in vitro and reduce atherosclerosis in apolipoprotein E deficient mice. (2018) (5)
- Detection of human papillomavirus oncoprotein E7 in liquid-based cytology. (2012) (4)
- 55. STUDIES OF ANTIBODIES AND IMMUNOGLOBULIN LEVELS IN URINE FROM CHILDREN WITH URINARY TRACT INFECTIONS CAUSED BY E. COLI (1970) (4)
- Nasal administration of Schistosoma mansoni egg antigens-cholera toxin B subunit conjugate to infected mice reduces immunopathology and mortality. (2001) (4)
- Letter: New enterotoxinogenic bacteria isolated. (1976) (4)
- The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross‐presenting dendritic cells (2011) (4)
- The Binding of Bacteria Carrying CFAs and Putative CFAs to Rabbit Intestinal Brush Border Membranes (1991) (4)
- Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide. (2009) (4)
- Natural Evolution and Human Consciousness (2014) (3)
- Identification and characterization of cholera exotoxin in culture filtrates of V. cholerae. (1971) (3)
- Chemical and immunological characterisation of the major glucosamine-containing ganglioside of human tissues. (1974) (3)
- Serum levels of the carcinoma-associated antigen CA 50 in ulcerative colitis. (1987) (3)
- Interaction of cholera toxin and toxin derivatives with lymphocytes. III. Modulating effects in vivo by cholera toxin on the graft-versus-host reactivity of lymphoid cells: suggested inhibition of suppressor cells. (1978) (3)
- QUANTISATION OF VIBRIOCIDAL ANTIBODIES USING AGAR PLAQUE TECHNIQUES (2009) (3)
- New prospects for mucosal immunization: anti-infectious and anti-inflammatory vaccines (1998) (3)
- Cholera Immunity and Development and Use of Oral Cholera Vaccines for Disease Control (2020) (3)
- Immunological cross-reactivity betweenEscherichia coli heat-labile enterotoxin and cholera toxin A and B subunits (2007) (3)
- Lack of Fc Gamma Receptor IIIA Promotes Rather than Suppresses Humoral and Cellular Immune Responses after Mucosal or Parenteral Immunization with Antigen and Adjuvants (2017) (3)
- ELISA for the Study of Enterotoxic Diarrhoeal Diseases (1978) (3)
- Effect of experimental trichinosis on intestinal secretion and on local antibody formation to cholera toxin. (1980) (3)
- The antibody response in rabbits to E. coli O antigen. (1970) (3)
- Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. (2021) (3)
- The antibody response of children with pyelonephritis to different antigens of E. coli. (1968) (3)
- Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges. (2022) (2)
- 30. Capsular antibodies to Escherichia coli in relation to urinary trait infectious (UTI) (1971) (2)
- A Radial Diffusion Agar Plaque Technique for Estimation of the Avidity of Bactericidal Antibodies against Vibrio cholerae (1972) (2)
- Cholera Immunity and Cholera Vaccination (2008) (2)
- Cholera and Oral-Mucosal Anti-infectious and Anti-inflammatory Vaccines (1996) (2)
- Live Oral Cholera Vaccine A Preliminary Review of its Pharmacology and Clinical Potential in Providing Protective Immunity against Cholera (1995) (2)
- Enzyme‐linked immunosorbent assay for determination of antibodies to Vibrio cholere toxin‐coregulated pili (1992) (2)
- 1985 field trial of oral cholera vaccines in Bangladesh: background studies on the method of vaccine delivery, vaccine immunogenecity, and vaccine safety[book chapter] (1988) (2)
- Stool cyclic AMP in diarrhoea due to different causative organisms. (1985) (2)
- Antibodies to endotoxin from Vibrio cholerae measured by bactericidal and indirect hemagglutination tests. Differences in immunoglobulin classes and specificity. (1972) (2)
- A Novel Nonantibiotic, lgt-Based Selection System for Stable Maintenance of Expression Vectors in Escherichia coli and Vibrio cholerae (2017) (2)
- Pathogenic mechanisms and new perspectives in the treatment and prevention of enteric infections. (1982) (2)
- Intestinal immunoglobulin production after oral cholera vaccination in patients with IgA deficiency with or without IgG subclass deficiency. (1993) (1)
- An agar plaque method for quantitation of vibriocidal antibodies. (1971) (1)
- Human Cultural Evolution Is Completely Immersed in Natural Evolution (2019) (1)
- CHAPTER 61 – Engineered bacterial toxin vaccines and adjuvants (2006) (1)
- Comparison of different methods for serial dilution used in serological routine work. (1970) (1)
- Secretory Immunity to Vibrio Cholerae Bacteria and Cholera Toxin: Prospects for an Improved Cholera Vaccine (1985) (1)
- Isolation ofEscherichia coli heat-labile enterotoxin by affinity chromatography: Characterization of subunits (1980) (1)
- THE IMMUNE SYSTEM AND INFECTIOUS DISEASES (1975) (1)
- Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization by Vibrio cholerae El Tor (1996) (1)
- Generalized and Compartmentalized Mucosal Immune Responses in Humans: Cellular and Molecular Aspects (1996) (1)
- Current Status and Prospects for Immunoprophylaxis in Cholera and Other Enterotoxic Enteropathies (1980) (1)
- Studies of Aggregates of IgG in Human Sera and Commercial γ-Globulin Preparations with a New Immuno-gel Filtration Method* (1972) (1)
- Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. (1999) (1)
- ThePrimary andSecondary Antibody Response to Escherichia coli 06Lipopolysacchari de Analysed atthe Humoral andCellular Level AMOUNT AND AVIDITYOF THE ANTIBODIESIN RELATIONTO PROTECTIVE CAPACITY (1973) (1)
- Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice (2000) (1)
- 1985 field trial of oral cholera vaccines in Bangladesh[book chapter] (1993) (1)
- Phenotypic characterization of circulating antibody-secreting cells after mucosal and systemic immunizations in humans. (1995) (1)
- Mucosal Immunity in the Gastrointestinal Tract in Relation to ETEC Vaccine Development (1989) (1)
- Cholera Toxin Induces a Transient Depletion of CD8+ Intraepithelial Lymphocytes in the Rat Small Intestine as Detected by Microarray and Immunohistochemistry (2005) (1)
- Cholera Toxin: Assembly, Secretion and in Vivo Expression (1991) (1)
- Cholera in breast-fed children (1985) (1)
- Consensus Meeting on International Standards for Oral Whole Cell Killed Cholera Vaccines, 17-18 May 2018, Seoul, Republic of Korea (2019) (1)
- Serotype has a significant impact on the virulence of 7th pandemic Vibrio cholerae O1 (2020) (0)
- in primary IgA nephropathy (1996) (0)
- Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin-β1 as strongly upregulated molecules involved in adjuvant activity (2019) (0)
- Receptor-Specific Large-Scale Purification on Silica Beads Derivatized with LysoGMl of Cholera Toxin Ganglioside (1981) (0)
- Chemical modification of cholera toxin for characterization of antigenic, receptor-binding and toxic sites. (1974) (0)
- Recombinant systems for expressing the cholera B subunit by using foreign promoters and / or leader peptides (1989) (0)
- Clinical trial of charocoal GM1 ganglioside in cholera and Escherichia coli enterotoxin diarrhea (1978) (0)
- oral cholera vaccine. with toxin in vitamin A-deficient rats immunized Impaired mucosal antibody response to cholera (2013) (0)
- The isolation of an oxidase negative strain of Pseudomonas aeruginosa from the urine of a cobalt irradiated patient. (2009) (0)
- Representation and use of formalin killed with e. coli bacteria, the colony-factor-antigen (CFA) expremieren for vaccination against the said enteric infection / diarrhea in humans initiating intestinal bacterium e. coli (1992) (0)
- Clinical trial of chlorproma (CPZ) as a therapent antisecretory agent in cholera (1978) (0)
- Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4. (2007) (0)
- 14 – Cholera Vaccines (2018) (0)
- TOXIN ABSORPTION IN CHOLERA (1981) (0)
- Immunological Aspects of Urinary Tract Infections (Part 1 of 2) (1975) (0)
- Peripheral tolerance and lymphocyte anergy (PP-072) (2010) (0)
- Incidence of enteric infections caused by different pathogens in children below 5 years of age ( GEMS study data adapted from Kotloff (2015) (0)
- Forthcoming papers (2006) (0)
- Oral B Subunit-Whole Cell Vaccine Against Cholera: From Basic Research to Successful Field Trial (1989) (0)
- Immunodiffusion studies of pneumococcal antigens with special reference to serotype 27. (2009) (0)
- Pathogenesis and prevention of cholera. (1982) (0)
- On secretory immuno globulin a (1969) (0)
- Expression of MIP-1alpha, MIP-1beta and RANTES mRNA in the genital tract and draining lymph nodes of mice infected with herpes simplex virus type 2 (1999) (0)
- Inflammasome-Dependent IL-1 Signaling Protein Kinase A and - Human Th17 Responses via Cyclic AMP Adjuvants mmCT and dmLT, Promote Cholera Toxin, and the Related Nontoxic (2015) (0)
- Receptor blocking, cholera, and Escherichia coli toxins. (1988) (0)
- Cholera Toxin B Subunit Powerful Induction by Antigen Coupled to Regulatory T Cells in Oral Tolerance : B Lymphocytes Promote Expansion of (2008) (0)
- Immunological Aspects of Urinary Tract Infections (Part 2 of 2) (1975) (0)
- Chapter De(cid:2) cient IgAl immune response to nasal cholera toxin subunit B in primary IgA nephropathy (2008) (0)
- Detection of human papillomavirus oncoprotein E 7 in liquid-based cytology (2012) (0)
- Hepatitis-infectious-mononucleosis antibody test. (1968) (0)
- Immunogenic and tolerogenic properties of mucosal administrated antigens linked to cholera and E. Coli heat-labile enterotoxin B subunits: A comparative study (1997) (0)
- Evaluation of Protective Immunity and Immunogenicity of a Killed Whole-cell Cholera Vaccine Containing Cholera Toxin B Subunit in a Murine Pneumonia Model (2014) (0)
- Regulatory T Cells + Tolerance and Foxp3 Lymphocytes for Mucosal Antigen-Induced RIIB on B g Important Role for Fc (2013) (0)
- 18 – Diarrhea Caused by Bacteria (2018) (0)
- Athymic (Nude) Mice for the Study of Gut Mucosal Immunity to Cholera Toxin (1987) (0)
- Cholera in breast fed infants : is low prevalence of hospitalization due to behavioural vs biological factors[abstract] (1981) (0)
- Immunodiffusion studies on pneumococcal antigens with special reference to serotype 27. (1971) (0)
- Oral B Subunit-whole cell cholera vaccine[book chapter] (1993) (0)
- Chapter 48 – Enteric Bacterial Vaccines: Salmonella, Shigella, Vibrio cholerae, Escherichia coli (2005) (0)
- Immune Response to Vibrio cholerae Infection in Rabbits with Special Reference to Antibodies Against in vivo Specific Antigens (1991) (0)
- Arthur Stoll 1887–1971 (1971) (0)
- Oral administration to NOD mice of diabetic autoantigens: Pure and linked to cholera toxin B subunit (1997) (0)
- S100A4 exerts robust mucosal adjuvant activity for co-administered antigens in mice (2022) (0)
- [An effective peroral cholera vaccine developed in Sweden]. (1989) (0)
- Use of a specific tumor-associated antigens, sialosyllactotetraose, cancer diseases concerning in diagnosis or therapy. (1985) (0)
- Expression of the binding subunit of cholera toxin using foreign promoters and / or leader sequences (1989) (0)
- Single-strain improved oral cholera vaccine : scientific report- Jan Holmgren (2015) (0)
- [Local IgA antibody formation after vaccination against cholera and poliomyelitis]. (1979) (0)
- Immunomodulation at Mucosal Surfaces: Prospects for the Development of Antiinfectious and Antiinflammatory Vaccines (2020) (0)
- Public behaviour and the response to pandemic infl uenza (2012) (0)
- Mucosal vaccine strategies (2020) (0)
- Expansion of gamma-interferon producing cell populations in the intestinal mucosa after peroral immunisation in humans (1990) (0)
- Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines (2019) (0)
- Immunoglobulin Class Avidity, and Pyelonephritis: Amount, in Experimental Local Antibody Production (2013) (0)
- Vaccination of humans intranasally with cholera toxin B-subunit induces antibody responses in vaginal and nasal secretions as well as in serum (1997) (0)
- Studies on the sensitivity of Proteus mirabilis and Proteus vulgaris to sulphonamide and colistin alone and in combination. (1970) (0)
- A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine. (2023) (0)
- Nontoxic B Subunit of Cholera Toxin CpG Oligodeoxynucleotide Linked to the Novel Immunostimulatory Agent Based on (2006) (0)
- Autoimmune Encephalomyelitis T Cells and Protect against Experimental Regulatory + Induce Antigen-Specific Foxp3 Antigen Coupled to Cholera Toxin B Subunit B Lymphocytes Treated In Vitro with (2012) (0)
- Spontaneous gamma-interferon production by human tonsillar lymphocytes: regulation of secretion by interleukin-1 (1990) (0)
- Studies on protective effect of O and K antibodies against E. coli bacteria with regard to the immunoglobulin class. (1971) (0)
- Suppression of allergic reactions by transdermal administration of allergens associated with or conjugated to the toxin subunits, or fragments thereof (2002) (0)
- Monoclonal antibodies against human papillomavirus E7 oncoprotein for diagnosis of cervical neoplasia and cancer (2012) (0)
- Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model of Helicobacter pylori Infection (2004) (0)
- Women Peasant Poets in Eighteenth-Century England, Scotland, and Germany. Milkmaids on Parnassus (2004) (0)
- Four German Stories: Vier Familiengeschichten fur unsere Zeit (2003) (0)
- Tomorrow We'll Be in Switzerland: Saving the Children of La Hille. (Morgen sind wir in der Schweiz: Die Rettung der Kinder von La Hille) (2002) (0)
- COMMENTARY (2007) (0)
This paper list is powered by the following services:
Other Resources About Jan Holmgren
What Schools Are Affiliated With Jan Holmgren?
Jan Holmgren is affiliated with the following schools:
